AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Indivior PLC

Report Publication Announcement Oct 15, 2020

4923_rns_2020-10-15_1963b6c9-ee68-4ec5-be68-30a2f8c52d16.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 1314C

Indivior PLC

15 October 2020

Indivior to Announce 2020 Year-to-Date and Q3 Results October 29th

Slough, UK, and Richmond, VA, 15 October 2020 - Indivior PLC (LON: INDV) today announced that it will release its 2020 year-to-date and third quarter results on Thursday, October 29th at 11:00 London time (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the Company's website at www.indivior.com.

Key members of Indivior's leadership team led by Mark Crossley, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 12:00 London time (8:00 a.m. U.S. Eastern) on October 29th.

Access the Live Results Webcast October 29th

The webcast event will be available on the "Investors" section of the Company's website at www.indivior.com. The webcast link is https://edge.media-server.com/mmc/p/py8oqyrx. Participants also may access the results presentation telephonically: US participants +1-646-741-3167; international participants +44 (0) 2071-928338. Please reference confirmation number 6570529. A replay of the presentation will be available at www.indivior.com.

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.

Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or [email protected]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOREAPELFDLEFFA

Talk to a Data Expert

Have a question? We'll get back to you promptly.